Jasper Therapeutics (NASDAQ:JSPR) Price Target Cut to $48.00 by Analysts at Royal Bank of Canada

Jasper Therapeutics (NASDAQ:JSPR) had its target price trimmed by Royal Bank of Canada from $68.00 to $48.00 in a report published on Thursday,Benzinga reports. The firm currently has an outperform rating on the stock.

JSPR has been the subject of several other reports. HC Wainwright reaffirmed a “buy” rating and set a $65.00 price objective on shares of Jasper Therapeutics in a research note on Thursday, October 24th. JMP Securities reaffirmed a “market outperform” rating and set a $70.00 price target on shares of Jasper Therapeutics in a report on Monday. Finally, BMO Capital Markets assumed coverage on shares of Jasper Therapeutics in a research report on Friday, December 6th. They set an “outperform” rating and a $63.00 price objective for the company. Ten investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $70.88.

Jasper Therapeutics Stock Performance

NASDAQ JSPR opened at $6.99 on Thursday. The firm’s fifty day moving average is $21.66 and its two-hundred day moving average is $20.37. Jasper Therapeutics has a one year low of $6.61 and a one year high of $31.01. The firm has a market cap of $104.86 million, a PE ratio of -1.47 and a beta of 2.18.

Institutional Trading of Jasper Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Bank of New York Mellon Corp acquired a new stake in shares of Jasper Therapeutics during the 2nd quarter valued at approximately $740,000. Rhumbline Advisers purchased a new stake in Jasper Therapeutics during the second quarter worth $300,000. American Century Companies Inc. grew its holdings in Jasper Therapeutics by 27.1% in the second quarter. American Century Companies Inc. now owns 14,204 shares of the company’s stock valued at $322,000 after purchasing an additional 3,032 shares during the last quarter. Wolff Wiese Magana LLC purchased a new position in shares of Jasper Therapeutics in the third quarter valued at $59,000. Finally, Fernwood Investment Management LLC boosted its position in shares of Jasper Therapeutics by 6.9% in the 3rd quarter. Fernwood Investment Management LLC now owns 52,897 shares of the company’s stock worth $995,000 after buying an additional 3,427 shares in the last quarter. Institutional investors and hedge funds own 79.85% of the company’s stock.

Jasper Therapeutics Company Profile

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.